Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Looking back to see ahead: study aims to spot CJD faster

NCT ID NCT07589283

Knowledge-focused Sponsor: First Affiliated Hospital of Fujian Medical University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks back at the medical records of 150 people diagnosed with Creutzfeldt-Jakob disease (CJD), a rare and fast-moving brain disorder. Researchers will examine symptoms, blood tests, spinal fluid, brain scans, and EEG results to find patterns that could help doctors diagnose CJD more quickly. No new treatments or tests are given—this is purely an observational study to gather knowledge.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this study could help doctors recognize Creutzfeldt-Jakob disease faster and more accurately in routine practice.
What could go wrong
This is a retrospective review of existing records, not a treatment trial. It cannot prove any new therapy works, and findings may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 150 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2022

Expected to finish

Dec 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study population consists of patients who were diagnosed with Creutzfeldt-Jakob Disease (CJD) at the First Affiliated Hospital of Fujian Medical University between Jan 01, 2022 and Dec 31, 2031. Potential participants were identified through a search of the hospital's electronic medical record system using diagnostic codes for CJD and related prion diseases. All patients who met the inclusion and exclusion criteria and had sufficient medical record data available for abstraction were included in the analysis. No additional recruitment or active enrollment was performed, as this was a retrospective chart review study. The study population is expected to reflect the typical clinical presentation and diagnostic workup of CJD in a real-world hospital setting.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of definite or probable Creutzfeldt-Jakob Disease (CJD) according to the established WHO diagnostic criteria * Available medical records covering at least one of the following: clinical history, peripheral blood test results, cerebrospinal fluid (CSF) analysis findings, brain MRI reports/images, or EEG reports * Hospitalized or evaluated at the participating institution during the study period Exclusion Criteria: * Alternative diagnosis confirmed that explains all clinical features (e.g., autoimmune encephalitis, rapidly progressive dementia due to other causes) * Incomplete medical records with no relevant clinical, laboratory, imaging, or EEG data available * Patient or legal representative declined the use of medical records for research purposes (where applicable according to local regulations)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Creutzfeldt-Jakob disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Creutzfeldt Jacob disease inherited Creutzfeldt-Jakob disease prion disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Creutzfeldt-Jakob disease (CJD) | prion disease

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.